Pharma Journalist -

Aurinia Pharmaceuticals Inc. announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS (voclosporin), based on an independent analysis issued by the…
Read More...

SMi Reports: Gain insights into the industry acceleration towards connectivity following the pandemic through case studies on connected devices and virtual studies. Key Themes for…
Read More...

SMi Reports: SMi Group is proud to introduce some insightful content from expert speaker of the upcoming Parallel Trade conference, taking place 22nd – 23rd March. The conference…
Read More...

HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like…
Read More...

Novavax, Inc. a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease…
Read More...

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra…
Read More...

Orgenesis Inc. a global biotech company working to unlock the full potential of cell and gene therapies,  announces that it has entered the planned second phase of a collaboration with…
Read More...

Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with I-Mab, an…
Read More...

SMi Group Reports: Exclusive interview with Lynne Ensor, Vice President, RCS Head of Global Compliance, Parexel International who will be chairing at SMi’s 4th Annual  Microbiology East…
Read More...

CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. announced a partnership to develop VBI’s enveloped virus like particle (eVLP) vaccine candidates against…
Read More...